Marina Pavlidou

Title: Marina Pavlidou: Innovator in Pharmaceutical Applications

Introduction

Marina Pavlidou is a notable inventor based in Freising, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative lipocalin muteins. With a total of two patents to her name, her work focuses on applications that can potentially transform treatment methodologies for various diseases.

Latest Patents

Marina's latest patents include the development of human tear lipocalin muteins that specifically bind to LAG-3. These muteins have promising applications as anti-cancer agents and immune modulators. They can be utilized in the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The patents also detail how these lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells that overexpress MHC class II. Furthermore, the disclosures encompass methods for generating these lipocalin muteins and nucleic acid molecules encoding them, along with their therapeutic and diagnostic uses.

Career Highlights

Throughout her career, Marina has worked with reputable companies such as Pieris Pharmaceuticals GmbH and Les Laboratoires Servier. Her experience in these organizations has allowed her to collaborate on groundbreaking research and development projects.

Collaborations

Some of her notable coworkers include Christine Rothe and Shane Olwill. Their collaborative efforts have contributed to the advancement of innovative solutions in the pharmaceutical industry.

Conclusion

Marina Pavlidou's work exemplifies the intersection of innovation and healthcare, showcasing her commitment to developing solutions that address critical medical challenges. Her contributions through patents and collaborations continue to pave the way for advancements in pharmaceutical applications.